2Wahbi N, Dalton RN, Turner C, et al. Dimethylarginines in chronic renal failure. J Clin Pathol, 2001, 54:470-473.
3Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans. Circulation, 2004, 109:172-177.
4Dimitrow PP, Undas A, Bober M, et al. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep, 2007, 59:715-720.
5Dayoub H, Rodionov R, Lynch C, et al. Overexpression of dimethylarginine dimet hylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke, 2008, 39:180-184.
6Vallance P,Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992, 339:572-575.
7Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res, 2005, 25:181-189.
8Zoccali C,Bode Boger, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet,2001, 358:113-2117.
9Jepson RE, Syme HM, Vallance C, et al. Plasma asymmetric dimethylarginine, symmetric dimethylarginine, 1 arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. J Vet Intern Med, 2008, 22:317-324.
10Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow up of the population study of women in Gothenburg. Arterioscler Thromb Vase Biol, 2008, 28:961 -967.
